Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Kidney Precision Medicine Project Tissue Interrogation Sites (U01 Clinical Trial Not Allowed)

Active
Grant

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

AI Contract Overview

Show more

The National Institutes of Health is soliciting applications for Tissue Interrogation Sites under the Kidney Precision Medicine Project to conduct detailed analysis of human kidney tissue specimens obtained from patients with acute or chronic kidney disease. These sites will work in close coordination with Recruitment Sites, the Kidney Tissue Atlas Coordinating Center, and the Central Hub to process and examine biopsy samples, aiming to generate a comprehensive Kidney Tissue Atlas that maps cellular and molecular features of kidney disease. The goal is to define distinct disease subgroups, identify key cell types and interstitial components, and uncover biological pathways and therapeutic targets that can inform the development of new precision treatments. The funding opportunity, designated as a U01 grant, explicitly prohibits clinical trials, focusing instead on the scientific interrogation of tissue samples to advance mechanistic understanding of kidney pathology. Applicants must demonstrate expertise in advanced tissue analysis techniques, bioinformatics, and multi-omics data integration. The project is administered by the Department of Health and Human Services, with point of contact Debbie S. Gipson, MS, MD, available for inquiries. All performance activities are to be conducted in the United States, and the solicitation was posted on September 10, 2025, with no set-aside provisions indicated.

General Info

NIH seeks sites to analyze kidney tissue samples for precision medicine research, creating a cellular atlas of kidney disease.

Agency

Department Of Health And Human Services → National Institutes Of HealthView Agency

NAICS

541714 - Research and Development in Biotechnology (except Nanobiotechnology)View NAICS

Place of Performance

Not specified

Set-Aside

NONE

Documents

(1)

RFA-DK-27-302-Full-Announcement.html

HTML

AI Contract Breakdown

Uniform Contract Format

What is UCF?

Uniform Contract Format (UCF) uses AI to break down any contract into standardized sections—scope, pricing, deliverables, and evaluation criteria.

Timeline

Posted

forecast

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyDepartment Of Health And Human Services → National Institutes Of Health
Contacts1 person available
OfficeUSA
Organization / Agency
Department Of Health And Human Services → National Institutes Of Health
View Agency Profile
Office AddressUSA
Contacts

Full Description

Show more
This Notice of Funding Opportunity (NOFO) requests applications for the Kidney Precision Medicine Project (KPMP) - Tissue Interrogation Sites (TIS) to analyze human kidney tissue. The TIS will collaborate with the Recruitment Sites (RS), Kidney Tissue Atlas Coordinating Center (KTACC) and Central Hub (CH) to obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) or chronic kidney disease (CKD), create a Kidney Tissue Atlas, define disease subgroups, and identify critical cells, interstitial components, pathways, and targets for novel therapies.

Similar Contracts

Same NAICS industry code

NAICS: 541714
New
Federal
Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA)
Solicitation # W911SR-26-R-HEAL
The Chemical, Biological, Radiological, and Nuclear (CBRN) Medical Countermeasure (MCM) Participant Basic Agreement (PBA) is a continuous, open solicitation designed to establish a dynamic, pre-qualified network of partners to accelerate the development and fielding of next-generation medical defenses against CBRN threats. Operated by the Capability Program Executive for CBRN Defense (CPE CBRND) under the Department of Defense, this agreement functions as an Indefinite-Delivery Indefinite-Quantity (IDIQ)-like vehicle authorized under 10 U.S.C. §§4021, 4022, and 4023, exempting it from the Competition in Contracting Act of 1984. The program seeks innovative, threat-agnostic host-directed therapeutics that enhance physiological resilience by targeting critical systems such as neurological function, respiratory stability, immune response, hematologic and vascular integrity, and cellular stress and repair pathways. Complementary to this, the government also seeks broad-spectrum therapeutic candidates that can directly neutralize CBRN agents, with emphasis on agents possessing environmental stability, non-cold-chain storage capability, and simplified administration routes like oral, intranasal, or autoinjector formats suitable for immediate use in austere, far-forward operational environments. Interested parties, including MCM developers at any stage from Phase I through FDA licensure and supporting organizations such as CROs, CDMOs, and regulatory experts, must submit a white paper of no more than five pages detailing product mechanisms, efficacy data from validated animal models, regulatory status including IND history and clinical trial results, manufacturing capacity and scale-up plans, and company experience. Collaboration is mandatory, with applicants required to state willingness to team or partner within the PBA ecosystem. Participation requires SAM registration, and all award decisions are based on technical merit and strategic alignment with the program’s mission to build a layered, resilient, and sustainable medical defense portfolio, without fixed deadlines or competitive bidding. The agreement supports the development of dual-use medical solutions with potential applications in civilian critical care, emphasizing ruggedized formulations, clear labeling, durable packaging, and long-term stability to ensure readiness in the most challenging operational conditions. Technical and administrative inquiries should be directed to Hunter Robinson or Alexander Mayatte at the Aberdeen Proving Ground, Maryland office.
W6QK Acc-Apg

POSTED

4 days ago

DEADLINE

N/A
View Details
NAICS: 541714
New
Federal
Pre-solicitation Notice: On-Ramp for the Department of Defense OMNIBUS IV Multiple-Award Contract
Solicitation # HT942626RE002
The Defense Health Agency Contracting Activity is preparing to issue an on-ramp to the OMNIBUS IV Multiple Award, Indefinite Delivery, Indefinite Quantity contract vehicle, which supports military medical research and development services across four distinct market segments: medical research and development support, general research and development support, regulatory processes for human and animal research, and translational science services for moving innovations from laboratory to clinical practice. This on-ramp opportunity is exclusively set-aside for small businesses certified under the Small Business Administration’s 8(a) Program, with the aim of expanding the pool of qualified contractors while maintaining alignment with the existing unrestricted contract vehicle. The OMNIBUS IV IDIQ has a cumulative ceiling of $10 billion and has already generated over $600 million in task order awards across 51 task orders since its base period began in 2022, with the majority of activity occurring in fiscal years 2024 through 2026. Task orders are competitively awarded, including set-asides for 8(a) participants, and may be issued by various DoD entities including DHACA, the Naval Supply Systems Command, and the Uniformed Services University of the Health Sciences. The upcoming solicitation, expected to be posted on SAM.gov in late February 2026, follows a delay to align with the February 2026 implementation of the FAR Overhaul, which significantly impacts how small business status is handled under unrestricted IDIQ contracts. Under the new rules, contractors do not need to recertify their small business status at the task order level when bidding on 8(a)-set-aside work, as they may rely on their original IDIQ-level size and status representation—even if they have graduated from the 8(a) Program or grown beyond small business size thresholds. However, contractors must still recertify their status at the IDIQ level within 60 to 120 days prior to the end of the fifth contract year, in compliance with FAR 19.301-2(b)(1)(iii)(A). Proposals must be submitted via the PIEE Solicitation module using a SAM.gov-registered account, and while the initial pre-solicitation notice provides the framework and intent, detailed evaluation criteria, submission instructions, and contract clauses will be formally outlined in the forthcoming RFP. All awards under this on-ramp will be made to small business 8(a) participants, and the government anticipates issuing multiple new contracts
Defense Health Agency

POSTED

6 days ago

DEADLINE

N/A
View Details

More opportunities from Department Of Health And Human Services → National Institutes Of Health

Same awarding agency

NAICS: 518210
Grant
Partnership with Common Fund Data Ecosystem ResourcesThe NIH Office of Strategic Coordination through its Common Fund is seeking partnerships between Common Fund data programs and external biomedical data resources to improve the reusability and integration of Common Fund datasets within broader scientific ecosystems. The initiative aims to advance the FAIR principles—Findable, Accessible, Interoperable, and Reusable—by fostering collaborations that bridge the Common Fund Data Ecosystem with other significant NIH data platforms such as the HEAL Data Ecosystem, BRAIN Initiative, Cancer Research Data Commons, ImmPort, TOPMed, and the Medical Imaging and Data Resource Center. These partnerships are intended to develop shared resources that enhance data connectivity, enable cross-platform analysis, and promote broader scientific utility of Common Fund data without supporting new clinical trials. The funding opportunity is open to non-CF biomedical data resources that can contribute infrastructure, tools, or expertise to amplify the impact of Common Fund datasets. Applicants must propose concrete plans for integration, interoperability, and sustainability of jointly developed resources. While no specific funding amount or deadline is indicated in the provided data, the solicitation was posted on August 6, 2026, and inquiries may be directed to the Common Fund Data Ecosystem Program via cfde@od.nih.gov. This effort reflects a strategic push by the NIH to unify diverse biomedical data ecosystems under common standards, enabling more comprehensive and efficient data-driven research across disciplines and institutions.
Computing Infrastructure Providers, Data Processing, Web Hosting, and Related Services

POSTED

18 days ago

DEADLINE

N/A
View Details